Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:55 PM
Ignite Modification Date:
2025-12-24 @ 11:55 PM
NCT ID:
NCT04603651
Eligibility Criteria:
Inclusion Criteria:
* Reside in a country where there are ongoing Lilly-sponsored clinical trials (currently this is only the United States)
* Present within 10 days of symptom onset
* Have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confirmed by reverse transcription polymerase chain reaction (RT-PCR) within the last three days
* Participants greater than or equal to (≥) 65 years of age OR
* Participants ≥ 12 years of age who weigh at least 40 kilograms AND have at least one of the following:
* Cancer
* Chronic kidney disease
* Chronic obstructive pulmonary disease (COPD) or other chronic lung disease
* Immunocompromised state (weakened immune system or on immunomodulatory medications)
* Obesity (body mass index \[BMI\] of 35 or higher)
* Serious heart conditions such as heart failure, coronary artery disease or cardiomyopathies
* Sickle cell disease
* Diabetes mellitus (Types 1 or 2)
Exclusion Criteria:
* Require hospitalization greater than (\>) 24 hours or hospice care. Residents in long term care or skilled nursing facilities that meet the inclusion criteria and are not on mechanical ventilation will be considered
* Bamlanivimab should not be used in patients hospitalized with severe COVID-19 respiratory disease
Sex:
ALL
Minimum Age:
12 Years
Study:
NCT04603651
Study Brief:
Protocol Section:
NCT04603651